FindTrial
Sign In

OPEN-LABEL, MULTICENTRE, PHASE 2 STUDY EVALUATING THE UTILITY OF 123I-nIBG SCINTIGRAPHYFOR ASSESSING ARRHYTHMIC RISK AS COMPARED TO ELECTROPHYSIOLOGY TESTING IN SUBJECTS WITH LEFT VENTRICULAR DYSFUNCTION

OPEN-LABEL, MULTICENTRE, PHASE 2 STUDY EVALUATING THE UTILITY OF 123I-nIBG SCINTIGRAPHYFOR ASSESSING ARRHYTHMIC RISK AS COMPARED TO ELECTROPHYSIOLOGY TESTING IN SUBJECTS WITH LEFT VENTRICULAR DYSFUNCTION

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-000742-21-IT
Enrollment
100
Registered
2007-03-19
Start date
2005-06-09
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CARDIOVASULAR ASSESSING OF ARRHYTHMIC RISCK IN SUBBIECTS WITH LEFT VENTRICULAR DYSFUNCTION

Interventions

Trade Name: 123IMETAIODOBENZILGUANIDINA Pharmaceutical Form: Solution for infusion INN or Proposed INN: Other diagnostic radiopharmaceuticals for tumour detection CAS Number: 139755-80-9 Concentration

Sponsors

AMERSHAM HEALTH
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026